AA
ALLO icon

AlphaCentric Advisors’s Allogene Therapeutics ALLO Stock Holding History

AlphaCentric Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-5,100
Closed -$129K – 209
2020
Q4 		$129K Buy
5,100
+3,700
+264% +$121K 0.05% 96
2020
Q3 		$53K Buy
+1,400
New +$52.8K 0.03% 98

Other funds holding ALLO

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

AlphaCentric Advisors's ALLO Position: Q1 2021 in Review

AlphaCentric Advisors sold out of Allogene Therapeutics (ALLO) in Q1 2021, closing a stake of 5,100 shares — an estimated $129K sold.

AlphaCentric Advisors first reported a position in ALLO in Q3 2020 and held it in 2 quarters. The position peaked at $129K in Q4 2020. 169 funds tracked by Wall St. Rank hold ALLO as of Q1 2021.

  • AlphaCentric Advisors reported no remaining Allogene Therapeutics position as of Q1 2021 after selling out during the quarter.
  • AlphaCentric Advisors sold 5,100 Allogene Therapeutics shares in Q1 2021, an estimated $129K.
  • AlphaCentric Advisors first reported a position in Allogene Therapeutics in Q3 2020 and held it in 2 quarters.
  • AlphaCentric Advisors's Allogene Therapeutics position peaked at $129K in Q4 2020.
  • 169 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2021.

Based on AlphaCentric Advisors's 13F filing for Q1 2021, filed 9 Mar 2022.